Benzodiazepine-Refractory Status Epilepticus - Which Drug is Second-Line?

December 27, 2019 00:23:35
Benzodiazepine-Refractory Status Epilepticus - Which Drug is Second-Line?
Critical Care Perspectives in Emergency Medicine
Benzodiazepine-Refractory Status Epilepticus - Which Drug is Second-Line?

Dec 27 2019 | 00:23:35

/

Show Notes

Up to one-third of patients with status epilepticus will not respond to benzodiazepines.  Unfortunately, treatment of benzodiazepine-refractory status epilepticus is not well studied.  The longer seizures persist, the worse patients do.  In this podcast, we discuss the results of the recently completed ESETT trial that evaluated three anticonvulsant medications for status epilepticus.

You can get CME credit for this episode here!Click here for CME Account Creation Instructions

Other Episodes

Episode 0

July 02, 2020 00:46:15
Episode Cover

Updates in the Critical Care Management of COVID-19 Patients

There has been an explosion of literature on the evaluation and management of patients with COVID-19 infection.  In this podcast, we discuss updates (as...

Listen

Episode 0

February 18, 2020 00:19:11
Episode Cover

Roc vs. Sux - The CURASMUR Trial

The debate on the ideal neuromuscular blocking agent for RSI in emergency intubations rages on. In this podcast, we review the latest randomized trial...

Listen

Episode 0

December 31, 2021 00:25:01
Episode Cover

The BOUGIE Trial

More than 1.5 million patients are intubated each year in the United States.  In up to 20% of patients, the first attempt at intubation...

Listen